{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-017913","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.781681+00:00","generated_at":"2026-06-17T02:54:32.800175+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"STRATA Skin pre-announces Q1 2023 revenue $7.3-$7.8M, best Q1 since 2016","bullets":["Preliminary Q1 2023 revenue $7.3-$7.8 million, strongest first quarter since 2016.","Placed 44 TheraClear X devices in Q1; over 3,000 treatments sold since Jan 2023 launch.","Converted 86 Pharos accounts to XTRAC devices from RaMedical acquisition.","CEO Bob Moccia cites strong sales momentum and expects meaningful revenue impact in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-017913","json":"https://secwatch.observer/filing/0001140361-23-017913.json","markdown":"https://secwatch.observer/filing/0001140361-23-017913.md","text":"https://secwatch.observer/filing/0001140361-23-017913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123017913/0001140361-23-017913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123017913/brhc20051325_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:54:32.800175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb71902a933f0159fd87c3740f9d9318b69dc211","claim":"STRATA Skin Sciences, Inc. reported first fiscal quarter of 2023 results: revenue range of $7.3 - $7.8 million.","evidence_excerpt":"--- EX-99.1 2 brhc20051325_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STRATA Skin Sciences Pre-Announces First Quarter 2023 Results • Preliminary revenue to be within the range of $7.3 - $7.8 million and expected to be the strongest first-quarter results since first quarter of 2016 • Company exceeds plan with 44 TheraClear ® X placements in the first quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123017913/0001140361-23-017913-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first fiscal quarter of 2023"},{"label":"Revenue","value":"range of $7.3 - $7.8 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}